Board of Directors

Chairman of the Board since 2018. Member of the Remuneration Committee and the Audit Committee. MBA, CPA. He served as a Board Member in BioInvent between 2016– 2017. He has held senior executive and board positions at European and US based biotech companies. He held senior executive positions at royal Boskalis NV, GE Capital and Continental Canada Company and has been a consultant with McKinsey and an auditor with Price Waterhouse New York. Born 1958.

Other board appointments: Board member in Zealand Pharma A/S, Basilea International AG and Pharming Group NV. Director in AI Global Investments (Netherlands ) PCC Ltd.

Shareholding: 27,538
 

Member of the Board since 2022.

BA in Community Health from Brown University and a Certificate in Premedical Sciences from Columbia University. Previous Research Associate at the New York University School of Medicine. Currently Managing Director, Therapeutics at Redmile Group, LLC. Born 1990.

Other board appointments: Redx Pharma Plc and Sensorion SA. 

Shareholding: -
 

Member of the Board since 2023.

M.Sc. in Chemical biology. Elin has worked at the university (KTH) and pharma and biotech industry since 2012 and has experience in antibody discovery and high-throughput analysis. Born 1985.

Other board appointments: -

Shareholding: 92 (affiliated holdings)

Conditional Employee Options: Option program 2022/2024: 3,099; option program 2023/2025: 1,266; option program 2024/2026: 498

Member of the Board since 2020.

Broad experience from the financial industry, operative in banking and finance between 1989 – 2012, with experience from asset management, institutional equity sales and investment banking. Previously held senior positions at Svenska Handelsbanken AB, Deutsche Bank AG and Nordea Bank AB and served as board member of the Swedish Securities Dealers Association. Board member of BioInvent during 2018-2019. Born 1968.

Other board appointments: Xbrane Biopharma AB.

Shareholding: 29,000
 

Member of the Board since 2020.

Doctor of Medicine. Previously experience as Vice President Marketing at Amgen Europe and has held various positions of increasing responsibility in clinical development, medical affairs and marketing at Amgen between 1989 and 2002. Prior to joining the biopharmaceutical industry, Thomas Hecht was certified in internal medicine and served as Co-Head of the Program for Bone Marrow Transplantation at the University of Freiburg, Germany. Currently Managing Partner at HHC Healthcare Consulting. Born 1951.

Other board appointments: Chairman of the board of Affimed N.V.

Shareholding: -
 

Member of the Board since 2024.

Chief Operating Officer at Sairopa BV, the Netherlands, since 2021. Laura has a Master of Science in Health Sciences from Maastricht University and has previously worked at several companies in the pharmaceutical sector, including the AstraZeneca Group (Acerta Pharma), PPD and ICON Clinical Research, conducting clinical studies for cancer treatment in senior positions. Born 1979.

Other board appointments: -

Shareholding: -
 

Member of the Board since 2022.

. PhD in Neuroscience from University College London, MBA from the University of Cambridge and a BA in Physiology and Psychology from the University of Oxford. Currently General Partner at Forbion. Prior experience with Apposite Capital and Novo Holdings. Nanna has previously served on the Board of Directors of publicly traded and privately held companies, including Inversago Pharma (acquired by Novo Nordisk), Lava Therapeutics (LVTX), Numab (asset spin-out Yellow Jersey acquired by J&J), ReViral (acquired by Pfizer), NBE Therapeutics (acquired by Boehringer Ingelheim), ObsEva (OBSV), IO Biotech (IOBT), Inventiva (IVA), Orphazyme (ORPHA), NodThera (private), MinervaX (private), and Stargazer (private). Born 1975.

Other board appointments: Board member in Capstan, F2G and Noema Pharma, board observer in Numab Therapeutics.

Shareholding: -
 

Member of the Board since 2025.
Tomas has worked in IT Management since 2007 at companies in manufacturing, medical distribution, and pharma. Born in 1981.

Other board appointments: -

Shareholding:1,240

Conditional Employee Options: Option program 2023/2025: 3,116. Option program 2024/2026: 1,466.

Member of the Board since 2018.

Doctor of Medicine and Doctor of Neurobiology. Previous experience as CEO and President of GPC Biotech, Executive Vice President and Chief Scientific Officer at Genome Therapeutics Corporation and Vice President of Oncology Drug Discovery and, in parallel, Vice President of Corporate and Academic Alliances, both at Bristol-Myers Squibb. Senior faculty positions at Harvard Medical School, Massachusetts General Hospital, and Princeton University. Born 1956.

Other board appointments: Board member and chairman of multiple public and private biotech companies in the United States, Europe, and Canada, including Oxford BioTherapeutics, CryptoMedix Inc., Oncolytics Biotech Inc., Aprea AB, and Aptose Inc. Advisory board member/Senior Advisor to Biotech Venture Capital Funds such as Pureos BioVentures and Hadean Ventures.

Shareholding: 66,000